RPEP-09538 · 2024Of 199 neoantigen vaccine clinical trials, peptide vaccines dominate (64.8%), delivery platforms are shifting toward DC systems (16.1%) and LNP/LPX (11%), most trials are Phase I (59.8%), and combination with immune checkpoint inhibitors is the primary development strategy.
Wu, Da-Wei; Jia, Shuo-Peng; Xing, Shu-Jun; Ma, Hai-Lan; Wang, Xin; Tang, Qi-Yu; Li, Zi-Wei; Wu, Qing; Bai, Min; Zhang, Xin-Yong; Fu, Xiao-Feng; Jia, Ming-Ming; Tang, Yu; Chen, Li; Li, Ning · Review
RPEP-09539 · 2024Low plasma NPY levels independently predicted PHN development in 182 herpes zoster patients, and combining NPY with clinical factors (age, pain severity, rash area) improved predictive accuracy from AUC 0.804 to 0.873.
Wu, Dan; Li, Fang; Yang, Feifei; Liu, Jun · Cohort
RPEP-09540 · 2024GLP-1 agonist therapy was associated with an adjusted odds ratio of 5.8 (95% CI 1.7-19.3, p=0.004) for residual gastric contents in fasting patients, with 19% of GLP-1 users showing visible food at endoscopy versus 5% of controls.
Wu, Fei; Smith, Matthew R; Mueller, Ariel L; Klapman, Seth A; Everett, Lucinda L; Houle, Timothy; Kuo, Braden; Hobai, Ion A · Cohort
RPEP-09541 · 2024SmBiT-conjugated R3/I5 chimeric peptide binds LgBiT-RXFP3 and LgBiT-RXFP4 with nanomolar affinity and minimal non-specific binding, enabling robust saturation and competition binding assays from whole cells and frozen membranes without ligand separation.
Wu, Hongkang; Hoare, Bradley L; Handley, Thomas N G; Akhter Hossain, Mohammed; Bathgate, Ross A D · In Vitro
RPEP-09542 · 202443 new lactoferricin variants were identified from mammalian lactoferrins across six taxonomic families (Primates, Rodentia, Artiodactyla, Perissodactyla, Pholidota, Carnivora), expanding the known LFcin family and its food preservation potential.
Wu, Jiajia; Zang, Mingwu; Wang, Shouwei; Qiao, Xiaoling; Zhao, Bing; Bai, Jing; Zhao, Yan; Shi, Yuxuan · Review
RPEP-09543 · 2024CPPs are a versatile platform for enhancing protein permeation across multiple mucosal barriers, with route-specific optimization needed to address the distinct structural and physicochemical challenges of nasal, buccal, sublingual, and oral mucosa.
Wu, Jiamin; Roesger, Sophie; Jones, Natalie; Hu, Che-Ming J; Li, Shyh-Dar · Review
RPEP-09544 · 2024Ure2 amyloidogenic peptide-resilin hybrid proteins self-assemble into supramolecular hydrogels with simultaneous wet adhesion, self-healing, rapid gelation, cell growth promotion, and hemostasis, outperforming commercial counterparts in tissue engineering and wound healing applications.
Wu, Junjun; Zhou, Lin; Peng, Hu; Wang, Zhaojun; Wang, Zhaoshi; Keasling, Jay D; Liu, Shike; Zhou, Guanghong; Ding, Shijie; Wang, Qiong; Wang, Xuejian; Chen, Xinxiu; Lang, Yifei; Xia, Mo; Guan, Xin; Dong, Mingsheng; Zhou, Jingwen; Chen, Jian · In Vitro
RPEP-09545 · 2024Semaglutide significantly reduced fibrosis markers (ACTA2, COL1A1, FN), inflammatory cytokines (TNF-α, IL-6, NF-κB), and epithelial-mesenchymal transition markers (vimentin, E-cadherin, N-cadherin) in both TGF-β1-induced endometrial cell and surgically-induced mouse models of intrauterine adhesions.
Wu, Luming; Zhan, Yue; Wang, Yiqing · Animal Study
RPEP-09546 · 2024BLAP responds specifically to MRSA-secreted β-lactamase by assembling in situ into nanofibrous networks that physically trap the bacteria, preventing host cell invasion and significantly reducing infection and abscess formation in mice.
Wu, Minghao; Li, Yuting; Shen, Huaxing; Zhang, Yanan; Cong, Wei; Hu, Xiaochun; Shi, Yejiao; Hu, Honggang · In Vitro
RPEP-09547 · 2024Three ACE-inhibiting tripeptides (WRP IC50 46.7 μM, YRP IC50 89.6 μM, WSR IC50 300.1 μM) were identified from fermented milk, with molecular dynamics confirming stable enzyme binding for WRP.
Wu, Nan; Li, Puyu; Shuang, Quan; Wuhanqimuge · In Vitro
RPEP-09548 · 2024Borneol-functionalized lipid nanoparticles delivered exenatide across the BBB at 4.21× the rate of conventional LNPs, reducing α-synuclein to 51.85% and increasing dopamine to 1.85× in Parkinson's disease mice.
Wu, Xiaomei; Yuan, Renxiang; Xu, Yichong; Wang, Kai; Yuan, Hong; Meng, Tingting; Hu, Fuqiang · Animal Study
RPEP-09549 · 2024GLP-1RA + SGLT-2i combination therapy in elderly T2DM patients reduced HbA1c by an additional 0.26%, improved eGFR, lowered LDL by 0.56 mmol/L, raised HDL by 0.18 mmol/L, and reduced systolic BP by 3.15 mmHg — all without increased adverse events.
Wu, Yaping; Yang, Zhenxing; Cao, Qingqing · Meta Analysis
RPEP-09550 · 2024Across 17 animal studies, liraglutide improved bone imaging parameters, bone pathology, and bone maximum load while favorably altering bone metabolism markers, working through Wnt, AMPK/PGC1α, and OPG/RANKL/RANK pathways.
Wu, Zongyi; Deng, Wei; Ye, Yiming; Xu, Jie; Han, Deyu; Zheng, Yu; Zheng, Qun · Animal Study
RPEP-09551 · 2024Colonization with H. hepaticus, S. aureus, and R. pneumotropicus did not alter HFD-induced body weight gain, food intake, body composition, glycemic control, or responsiveness to liraglutide or MAR709 in C57BL/6J mice.
Wunderlich, Margit; Miller, Manuel; Ritter, Bärbel; Le Gleut, Ronan; Marchi, Hannah; Majzoub-Altweck, Monir; Knerr, Patrick J; Douros, Jonathan D; Müller, Timo D; Brielmeier, Markus · Animal Study
RPEP-09552 · 2024LL-37 accelerated diabetic wound healing by activating TFEB nuclear translocation, which upregulated autophagy markers ATG5, ATG7, and BECN1. Blocking autophagy or TFEB reversed LL-37's healing effects.
Xi, Liuqing; Du, Juan; Xue, Wen; Shao, Kan; Jiang, Xiaohong; Peng, Wenfang; Li, Wenyi; Huang, Shan · Animal Study
RPEP-09553 · 2024Tirzepatide (1.2 mg/kg twice weekly for 12 weeks) significantly reduced M1 adipose tissue macrophage infiltration, lowered inflammatory cytokines, and improved insulin sensitivity in obese mice through ERK pathway modulation and M1 macrophage apoptosis.
Xia, Yin; Jin, Jing; Sun, Yaqin; Kong, Xiaocen; Shen, Ziyang; Yan, Rengna; Huang, Rong; Liu, Xiaomei; Xia, Wenqing; Ma, Jingjing; Zhu, Xudong; Li, Qian; Ma, Jianhua · Animal Study
RPEP-09554 · 2024Scorpion venom-derived peptides (both DBPs and NDBPs) demonstrate broad-spectrum antimicrobial activity against bacteria, fungi, and parasites, with rapid killing action and low propensity for resistance development.
Xia, Zhiqiang; Xie, Lixia; Li, Bing; Lv, Xiangyun; Zhang, Hongzhou; Cao, Zhijian · Review
RPEP-09555 · 2024BmKn2-T5 inhibited EV71 dose-dependently in vitro, acting at early stages of the viral cycle. It also suppressed DENV, ZIKV, and HSV-1 replication, suggesting a shared early-stage viral target.
Xia, Zhiqiang; Wang, Huijuan; Chen, Weilie; Wang, Aili; Cao, Zhijian · In Vitro
RPEP-09556 · 2024Seven novel ACE inhibitory peptides were identified from eel bone collagen hydrolysates, with GPPGPPGL (IC50 535.84 μM) competitively binding ACE's S2 pocket. GPPGPPGL also increased nitric oxide and decreased endothelin-1 in HUVECs.
Xiang, Huan; Huang, Hui; Shao, Yanqiu; Hao, Shuxian; Li, Laihao; Wei, Ya; Chen, Shengjun; Zhao, Yongqiang · In Vitro
RPEP-09557 · 2024MGR (IC50 4.50 μM) and HDCF (IC50 26.38 μM) from garlic protein competitively inhibited ACE, survived gastrointestinal digestion, and lowered blood pressure in spontaneously hypertensive rats through renin-angiotensin system modulation.
Xiang, Lu; Zheng, Zhenjia; Guo, Xiaojing; Bai, Ruoxi; Zhao, Renjie; Chen, Haihua; Qiu, Zhichang; Qiao, Xuguang · Animal Study
RPEP-09558 · 2024Cationic module-programmed neoantigen peptides self-assembled with CpG into carrier-free nanoparticles that drove potent neoantigen-specific T-cell responses. Combined with anti-PD-1, they achieved significant inhibition or complete regression of melanoma and MC-38 colon tumors.
Xiang, Zhichu; Lu, Jianhua; Rao, Shangrui; Fu, Chenxing; Yao, Yuying; Yi, Yongdong; Ming, Yang; Sun, Weijian; Guo, Weisheng; Chen, Xiaoyuan · Animal Study
RPEP-09559 · 2024Food-derived bioactive peptides from multiple protein sources demonstrate hepatoprotective activity against alcoholic liver injury through antioxidant, anti-inflammatory, and anti-apoptotic pathways in preclinical studies.
Xiao, Chuqiao; Li, Xiang-Guang; Zhao, Mouming · Review
RPEP-09560 · 2024Milk exosome-liposome hybrid vesicles (mExos@DSPE-Hyd-PMPC) achieved 2.4× semaglutide encapsulation efficiency over natural exosomes and 8.7% oral bioavailability through pH-responsive surface adaptation that overcomes sequential gut absorption barriers.
Xiao, Peifu; Wang, Hanxun; Liu, Hongbing; Yuan, Haoyang; Guo, Chen; Feng, Yupeng; Qi, Pan; Yin, Tian; Zhang, Yu; He, Haibing; Tang, Xing; Gou, Jingxin · In Vitro
RPEP-09561 · 2024FDWLR from walnut protein (IC50 8.02 μg/mL ACE inhibition) demonstrated triple validation: in vitro ACE blocking, HUVEC vasoprotection against angiotensin II, and in vivo blood pressure lowering in spontaneously hypertensive rats.
Xie, Jinxiang; Chen, Shupeng; Huan, Pengtao; Wang, Shuguang; Zhuang, Yongliang · Animal Study
RPEP-09562 · 2024Retatrutide 12mg (−22.1% body weight, −17cm waist) and tirzepatide 15mg (−16.5%) were the most effective weight loss treatments. Dual/triple receptor agonists significantly outperformed single GLP-1 receptor agonists across 27 RCTs with 15,584 patients.
Xie, Zeyu; Zheng, Guimei; Liang, Zhuoru; Li, Mengting; Deng, Weishang; Cao, Weiling · Meta Analysis
RPEP-09563 · 2024From 2,398 FAERS reports (5,653 adverse events), 23 system organ classes and 93 preferred terms showed significant signals for oral semaglutide, with metabolism/nutrition disorders most signaled and unexpected findings of acute cholecystitis, abducens nerve paralysis, and positional vertigo.
Xiong, Si; Gou, Ruoyu; Liang, Xudong; Wu, Hao; Qin, Shuitao; Li, Bing; Luo, Changjun; Chen, Junan · Cohort
RPEP-09564 · 2024Liraglutide + standard therapy achieved 97.6% effectiveness vs 78.6% for standard therapy alone, with significantly better blood glucose control, kidney function (Scr, BUN, 24h-UPor), renal fibrosis reduction, and immunoglobulin levels in 84 T2DM patients.
Xiong, Wen; Liu, Hongxia; Xiang, Bo; Shang, Guangyu · Cohort
RPEP-09565 · 2024AIPH/AMP/MoS2 composite nanosheets achieved MIC of 38 μg/mL against MDR E. coli and 30 μg/mL against MDR S. aureus, destroyed >85% of biofilms under NIR irradiation, and healed ~90% of wounds in 4 days through synergistic photothermal, free radical, and AMP mechanisms.
Xu, Guanglin; Peng, Guanglan; Yang, Jianping; Wu, Mingcai; Li, Wanzhen; Wang, Jun; Zhu, Longbao; Zhang, Weiwei; Ge, Fei; Song, Ping · In Vitro
RPEP-09566 · 2024MHLAPre achieved significant improvement over five state-of-the-art models in identifying immunogenic neoepitopes for cancer immunotherapy, using meta-learning on MS-derived HLA ligandome data with transfer learning from pHLA-TCR interaction datasets.
Xu, Long; Yang, Qiang; Dong, Weihe; Li, Xiaokun; Wang, Kuanquan; Dong, Suyu; Zhang, Xianyu; Yang, Tiansong; Luo, Gongning; Liao, Xingyu; Gao, Xin; Wang, Guohua · Review
RPEP-09567 · 2024Ghrelin activated the hypothalamic AMPK-mTOR pathway to induce NPY production, alleviating cancer-induced bone pain in rats. NPY's antinociceptive effect was mediated through Y1 and Y2 receptors and reversed by GHS-R1α antagonism.
Xu, Longjie; Hou, Lili; Cao, Chun; Li, Xiaohua · Animal Study
RPEP-09568 · 2024Exenatide time-dependently modulates the hepatic circadian clock through CNS GLP-1 receptors. Morning-equivalent dosing (ZT12) counteracted clock disruption from irregular eating; evening-equivalent dosing (ZT0) worsened it. CNS GLP-1 receptor knockdown attenuated these effects.
Xu, Pingping; Morishige, Jun-Ichi; Jing, Zheng; Nagata, Naoto; Shi, Yifan; Iba, Tomohiro; Daikoku, Takiko; Ono, Masanori; Maida, Yoshiko; Fujiwara, Tomoko; Fujiwara, Hiroshi; Ando, Hitoshi · Animal Study
RPEP-09569 · 2024Among 448 NET patients, ¹⁷⁷Lu-DOTATATE (n=335) showed no significant renal toxicity difference from ⁹⁰Y-DOTATOC (n=113) but caused more hematological effects. ¹⁷⁷Lu-DOTATATE was associated with significantly longer PFS (HR 0.47, P=0.004) but no OS difference.
Xu, Tao; Dillon, Joseph S; Maluccio, Mary A; Quelle, Dawn E; Nash, Sarah H; Cho, Hyunkeun; Limbach, Kristen E; Skill, Nicholas J; Bren-Mattison, Yvette; O'Rorke, Michael A · Cohort
RPEP-09570 · 2024GLP-1 receptor agonists cause delayed gastric emptying that increases aspiration risk under anesthesia. Discontinuation before surgery is imperative, and SGLT-2 inhibitors pose a separate risk of severe diabetic ketoacidosis perioperatively.
Xu, Wen; Schmiesing, Cliff; Chang, James · Review
RPEP-09571 · 2024CATH-2 reduced IL-1β, IL-6, IL-1α, and IL-12 production during APEC infection by inhibiting NLRP3 inflammasome activation, NF-κB and MAPK signaling, and disrupting lysosomal function. Restoring lysosomal acidification reversed CATH-2's anti-inflammatory effects.
Xu, Yating; Xu, Liuyi; Zhang, Tingting; Tian, Hongliang; Lu, Yi; Jiang, Sha; Cao, Xuefeng; Li, Zhiwei; Hu, Xiaoxiang; Fang, Rendong; Peng, Lianci · In Vitro
RPEP-09572 · 2024Liraglutide significantly reduced BMI (MD −1.06), triglycerides (MD −0.35 mmol/L), visceral adipose tissue (MD −21.06 cm²), and subcutaneous adipose tissue (MD −20.53 cm²) in T2DM patients with NAFLD across 12 studies.
Xu, Yuan-Yuan; Wang, Xu; She, Yu-Qing; Liu, Jie; Zhang, Qing · Meta Analysis
RPEP-09573 · 2024Liraglutide (0.6 mg/kg for 12 weeks) protected against HFD-induced kidney injury by reducing serum lipids, improving kidney function markers, reversing kidney pathology, and inhibiting the CaMKKβ/AMPK signaling pathway. Bortezomib (AMPK agonist) partially reversed these effects.
Xuan, Yingli; Ding, Ting-Ting; Mao, Xiao-Lei; Pang, Shiqing; He, Ruibin; Qin, Li; Yuan, Jiang Zi · Animal Study
RPEP-09574 · 2024Oral semaglutide reduced HbA1c by −0.7% and body weight by −2.8 kg in 624 Japanese T2DM adults over 34-44 weeks. Benefits were maintained in patients ≥75 years (HbA1c −0.5%, weight −2.7 kg). 25.8% reported adverse events, mostly gastrointestinal.
Yabe, Daisuke; Hamamoto, Yoshiyuki; Kawanami, Daiji; Nishimura, Rimei; Terauchi, Yasuo; Amadid, Hanan; Braae, Uffe Christian; Major-Pedersen, Atheline; Suzuki, Ryo · Cohort
RPEP-09575 · 2024Post-treatment SPECT/CT imaging at 24 hours after PRRT provided qualitative response assessments that impacted clinical management decisions in 100 NET patients undergoing peptide receptor radionuclide therapy.
Yadav, Surekha; Lawhn-Heath, Courtney; Paciorek, Alan; Lindsay, Sheila; Mirro, Rebecca; Bergsland, Emily K; Hope, Thomas A · Cohort
RPEP-09576 · 2024Among 3,505 T2D patients in real-world practice, once-weekly semaglutide showed 24.3% AE rate (mostly mild GI), 5.1% discontinuation rate, 0.5% serious ADRs, and 0.1% severe hypoglycemia — consistent with phase 3 RCT safety data.
Yale, Jean-François; Major-Pedersen, Atheline; Catarig, Andrei-Mircea; Jain, Rashmi; Menzen, Markus; Holmes, Patrick · Cohort
RPEP-09577 · 2024Single-dose oxytocin trials consistently show efficacy for autism core symptoms, but repeated administration yields mixed results. Diminishing efficacy at higher/repeated doses may involve oxytocin-vasopressin receptor cross-talk and receptor desensitization.
Yamasue, Hidenori · Review
RPEP-09578 · 2024Semaglutide improved cardiac function, reduced histopathological damage, and altered the cardiac metabolomic profile after myocardial infarction in rats, suggesting cardioprotection through metabolic modulation rather than just glycemic control.
Yan, Haihao; Yao, Wenjing; Li, Yanhong; Li, Tianxing; Song, Kexin; Yan, Pan; Dang, Yi · Animal Study
RPEP-09579 · 2024Intranasal KAFAK peptide traversed the BBB in TBI mice, reduced proinflammatory cytokines contributing to secondary injury, and improved or restored neurological, memory, and locomotor function after moderate traumatic brain injury.
Yanamadala, Yaswanthi; Roy, Ritika; Williams, Afrika Alake; Uppu, Navya; Kim, Audrey Yoonsun; DeCoster, Mark A; Kim, Paul; Murray, Teresa Ann · Animal Study
RPEP-09580 · 2024The casein-derived tripeptide LLY demonstrated high ACE-inhibitory activity with excellent stability. Systematic investigation revealed the molecular details of LLY-ACE binding interactions important for understanding and designing antihypertensive peptides.
Yang, Cuicui; Xie, Tianzhao; Cai, Mengmeng; Xu, Xiaoting; Li, Muzijun; Liu, Pengru; Lan, Xiongdiao · In Vitro
RPEP-09581 · 2024SHP2 from seahorse hydrolysate protected keratinocytes from UVB by reducing ROS and apoptosis, inhibited MMPs in fibroblasts while promoting collagen synthesis, and demonstrated anti-photoaging effects in a zebrafish model.
Yang, Fengqi; Yang, Yang; Xiao, Dandan; Kim, Poongho; Lee, Jihee; Jeon, You-Jin; Wang, Lei · In Vitro
RPEP-09582 · 2024Heart-specific Nppb knockout improved sepsis-induced myocardial injury in mice. Seven differentially expressed genes overlapped with senescence genes, with CCL2 identified as the key mediator. Reducing Nppb lowered CCL2 expression and improved cardiac structure and function.
Yang, Hang; Jiang, Zhenjie; Feng, Lin; Wang, Chengyan; Xu, Haojie; Wu, Xiaodan; Lin, Caizhu; Zeng, Kai · Animal Study
RPEP-09583 · 2024Stapled peptide SM3-4 dual-targeted MDM2/MDMX, induced tumor cell apoptosis at low μM concentrations in vitro, showed significantly increased helicity compared to linear peptides, and demonstrated that enhanced staple activity correlates with helicity.
Yang, Jian; Liao, Xiufei; Hu, Damin; Mo, Jinqiu; Gao, Xiurong; Liao, Hongli · In Vitro
RPEP-09584 · 2024PM@GS/PCL scaffold achieved 17.81 ± 0.83 MPa compressive strength, promoted MSC osteogenic differentiation (alizarin red and ALP staining), enhanced HUVEC migration and tube formation, and improved bone repair and vascularization in a rat femoral defect model.
Yang, Jin; Fatima, Kanwal; Zhou, Xiaojun; He, Chuanglong · In Vitro
RPEP-09585 · 2024Tirzepatide across SURMOUNT/SURPASS trials achieved HbA1c reductions up to 2.24% and weight loss up to 11.2 kg with good tolerability. Cardiovascular benefits are promising based on surrogate markers but await dedicated outcome trials.
Yang, Jingqi; Gu, Yuncheng; Chen, Huaigang; Wang, Hong; Hong, Lang; Li, Bin; Yang, Liu · Review
RPEP-09586 · 2024Semaglutide restored HSDL2 expression and reduced oxidative stress markers in cardiomyocytes of obese mice, identifying a novel HSDL2-mediated pathway for GLP-1 agonist cardioprotection against obesity-induced heart damage.
Yang, Lin; Pan, Xiaoyu; Pan, Zhenyu; Gao, Haina; Ban, Jiangli; Chen, Shuchun · Animal Study
RPEP-09587 · 2024Meta-analysis of RCTs confirmed semaglutide significantly reduces body weight in overweight/obese adults with or without T2DM compared to placebo, with consistent effects across multiple anthropometric and metabolic outcomes.
Yang, Liu; Duan, Xueyu; Hua, Peng; Wu, Shilin; Liu, Xiaobo · Meta Analysis